Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy.
The results of a recently completed Phase III clinical trial suggest that concurrent chemoradiotherapy followed by tecemotide provides superior benefits to Stage IIIa and IIIb non-small cell lung carcinoma patients as compared with sequential chemoradiotherapy followed by tecemotide. These clinical observations will be dissected in a transgenic model of lung cancer that we have recently established (hMUC1.Tg C57BL/6 mice).
University of California, Davis; Department of Internal Medicine; Division of Hematology and Oncology; Sacramento, CA USA.
Chiao-Jung
CJ
Kao
University of California, Davis; Department of Internal Medicine; Division of Hematology and Oncology; Sacramento, CA USA.
Gregory T
GT
Wurz
ImmunoOncology; Merck Serono Research; Merck KGaA, Germany.
Andreas
A
Schröder
ImmunoOncology; Merck Serono Research; Merck KGaA, Germany.
Michael
M
Wolf
University of California, Davis; Department of Internal Medicine; Division of Hematology and Oncology; Sacramento, CA USA.
Michael W
MW
Degregorio
L-BLP25; anticancer vaccines; mucin 1; non-small cell lung carcinoma